Effectiveness of probiotics in the treatment of irritable bowel syndrome

Pharmacotherapy

Volumn 28, Issue 4, 2008, Pages 496-505

  Wilhelm, Sheila M ^a,b   Brubaker, Christine M ^a   Varcak, Elizabeth A ^a   Kale Pradhan, Pramodini B ^a,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

^c ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Alosetron; Bacteria; IBS; Irritable bowel syndrome; Probiotics; Tegaserod

Indexed keywords

BB 99; LACTEOL FORT; LC 705; PLACEBO; PRESCRIPT ASSIST; PROBIOTIC AGENT; PROVIVA; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; BACTERIAL COUNT; BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; CLINICAL TRIAL; DATA BASE; DEFECATION HABIT; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; DRUG WITHDRAWAL; FLATULENCE; HUMAN; INTESTINE TRANSIT TIME; IRRITABLE COLON; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS HELVETICUS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS SALIVARIUS; PROPIONIBACTERIUM FREUDENREICHII SHERMANII; REVIEW; STREPTOCOCCUS SALIVARIUS; SYMPTOM; UNSPECIFIED SIDE EFFECT;

ABDOMINAL PAIN; CONTROLLED CLINICAL TRIALS AS TOPIC; DEFECATION; FLATULENCE; GASTROINTESTINAL TRANSIT; HUMANS; IRRITABLE BOWEL SYNDROME; PROBIOTICS;

EID: 41549131731     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.4.496     Document Type: Review

References (26)

1. Riordan S, Kim R. Bacterial overgrowth as a cause of irritable bowel syndrome. Curr Opin Gastroenterol 2006;22:669-73.
2. Tillisch K, Labus JS, Naliboff BD, et al. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol 2005;100:896-904.
3. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004;292:852-8.
4. American Gastroenterological Association. American Gastroenterological Association medical position statement: irritable bowel syndrome. Gastroenterology 2002;123:2105-7.
5. Thompson WG. The road to Rome. Gut 1999;45(suppl 2):II80-1.
6. Foxx-Orenstein A. IBS: review and what's new [article online]. MedGenMed 2006;8:20.
7. Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007;19:166-72.
8. Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. AmJ Clin Nutr 2001;73:399S-405.
9. McCarthy J, O'Mahony L, O'Callaghan L, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003;52:975-80.
10. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll like receptor 9 signalling mediates experimental colitis. Gastroenterology 2004;126:520-8.
11. Kale-Pradhan PB, Wilhelm SM. Tegaserod for constipation- predominant irritable bowel syndrome. Pharmacotherapy 2007;27:267-77.
12. Tsuchiya J, Barreto R, Okura R, Kawakita S, Fesce E, Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chinese J Dig Dis 2004;5:169-74.
13. Kajander K, Hatakka K, Poussa T, Farkkilas M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005;22:387-94.
14. Whorwell P, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-90.
15. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001;13:1143-7.
16. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterol 2005;128:541-51.
17. Halpern GM, Prindiville T, Blankenburg M, Hsia T, Gershwin ME. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 1996;91:1579-85.
18. Nobaek S, Johansson M, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-8.
19. Kim H, Camilleri M. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904.
20. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC55730 in the treatment of patients with irritable bowel syndrome: a double-blind, placebo-controlled randomized study. Clin Nutr 2005;24:925-31.
21. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JD. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002;47:2615-20.
22. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007;26:475-86.
23. Kim H, Roque MV, Camilleri M. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005;17:687-96.
24. O'Sullivan M, O'Morain C. Bacterial supplementation in the irritable bowel syndrome: a randomized double-blind placebo-controlled crossover study. Dig Liver Dis 2000;32:294-301.
25. Bittner AC, Croffut RM, Stranahan MC. Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodological oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clin Ther 2005;27:755-61.
26. Talley N, Nyren O, Drossman D. The irritable bowel syndrome: toward optimal design of controlled treatment trials. Gastroenterol Int 1993;6:189-211.